1,694
Views
10
CrossRef citations to date
0
Altmetric
Editorial

Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients

ORCID Icon & ORCID Icon
Article: 2005859 | Received 07 Nov 2021, Accepted 09 Nov 2021, Published online: 23 Nov 2021

References

  • Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000337. doi:10.1136/jitc-2019-000337.
  • Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–3. doi:10.1038/nri.2016.107.
  • Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–1059. doi:10.1038/nm1622.
  • Liu P, Zhao L, Loos F, Iribarren K, Lachkar S, Zhou H, Gomes-da-silva LC, Chen G, Bezu L, Boncompain G, et al. Identification of pharmacological agents that induce HMGB1 release. Sci Rep. 2017;7:14915. doi:10.1038/s41598-017-14848-1.
  • Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2014;21:69–78. doi:10.1038/cdd.2013.72.
  • Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L, et al. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy. 2015;11:1878–1890. doi:10.1080/15548627.2015.1082022.
  • Ladoire S, Enot D, Senovilla L, Ghiringhelli F, Poirier-Colame V, Chaba K, Semeraro M, Chaix M, Penault-Llorca F, Arnould L, et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy. 2016;12:864–875. doi:10.1080/15548627.2016.1154244.
  • Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH. Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer. Cancer Immunol Immunother. 2020;69:355–364. doi:10.1007/s00262-019-02458-x.
  • Exner R, Sachet M, Arnold T, Zinn‐Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M, et al. Prognostic value of HMGB 1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med. 2016;5:2350–2358. doi:10.1002/cam4.827.
  • Clasen K, Welz S, Faltin H, Zips D, Eckert F. Dynamics of HMBG1 (high mobility group box 1) during radiochemotherapy correlate with outcome of HNSCC patients. Strahlenther Onkol. 2021. doi:10.1007/s00066-021-01860-8.